• Genentech, part of Roche, outlined plans to invest about USD 750 million to expand its Hillsboro, Oregon manufacturing campus.
• Project adds a device fill-finish facility for pre-filled syringes and autoinjectors, strengthening end-to-end US manufacturing capability.
• Expansion doubles the site’s size; expected to create 250 manufacturing jobs, 200 construction jobs.
• Commercial operations slated to start in 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202608201100BIZWIRE_USPR_____20260820_BW026839) on August 20, 2026, and is solely responsible for the information contained therein.